Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 9;5(6):zrab126.
doi: 10.1093/bjsopen/zrab126.

Outcome reporting in therapeutic mammaplasty: a systematic review

Alice Lee  1 , Richard M Kwasnicki  1 , Hasaan Khan  2 , Yasmin Grant  3 , Abigail Chan  2 , Angela E E Fanshawe  4 , Daniel R Leff  1
Affiliations

Outcome reporting in therapeutic mammaplasty: a systematic review

Alice Lee et al. BJS Open. .

Abstract

Background: Therapeutic mammaplasty (TM) is an oncological procedure which combines tumour resection with breast reduction and mastopexy techniques. Previous systematic reviews have demonstrated the oncological safety of TM but reporting of critically important outcomes, such as quality of life, aesthetic and functional outcomes, are limited, piecemeal or inconsistent. This systematic review aimed to identify all outcomes reported in clinical studies of TM to facilitate development of a core outcome set.

Methods: Medline, EMBASE, CINAHL and Web of Science were searched from inception to 5 August 2020. Included studies reported clinical outcomes following TM for adult women. Two authors screened articles independently for eligibility. Data were extracted regarding the outcome definition and classification type (for example, oncological, quality of life, etc.), time of outcome reporting and measurement tools.

Results: Of 5709 de-duplicated records, 148 were included in the narrative synthesis. The majority of studies (n = 102, 68.9 per cent) reported measures of survival and/or recurrence; approximately three-quarters (n = 75, 73.5 per cent) had less than 5 years follow-up. Aesthetic outcome was reported in half of studies (n = 75, 50.7 per cent) using mainly subjective, non-validated measurement tools. The time point at which aesthetic assessment was conducted was highly variable, and only defined in 48 (64.0 per cent) studies and none included a preoperative baseline for comparison. Few studies reported quality of life (n = 30, 20.3 per cent), functional outcomes (n = 5, 3.4 per cent) or resource use (n = 28, 18.9 per cent).

Conclusion: Given the oncological equivalence of TM and mastectomy, treatment decisions are often driven by aesthetic and functional outcomes, which are infrequently and inconsistently reported with non-validated measurement tools.

PubMed Disclaimer

Figures

<sc>Fig.</sc> 1
Fig. 1
PRISMA flow chart BCS, breast-conserving surgery; TM, therapeutic mammaplasty.
See this image and copyright information in PMC

References

    1. Currie A, Chong K, Davies G.. Using therapeutic mammoplasty to extend the role of breast-conserving surgery in women with larger or ptotic breasts. Ann R Coll Surg Engl 2013;95:192–195. - PMC - PubMed
    1. Schaverien MV, Raine C, Majdak-Paredes E, Dixon JM.. Therapeutic mammaplasty – extending indications and achieving low incomplete excision rates. Eur J Surg Oncol 2013;39:329–333. - PubMed
    1. O'Connell RL, Rattay T, Dave RV, Trickey A, Skillman J, Barnes NLP. et al.; Breast Reconstruction Research Collaborative. The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study. Br J Cancer 2019;120:883–895. - PMC - PubMed
    1. Macmillan RD, James R, Gale KL, McCulley SJ.. Therapeutic mammaplasty. J Surg Oncol 2014;110:90–95. - PubMed
    1. McIntosh J, O'Donoghue JM.. Therapeutic mammaplasty – a systematic review of the evidence. Eur J Surg Oncol 2012;38:196–202. - PubMed

Publication types